US Organ-on-Chip Market Research Report: By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Application (Drug Discovery, Toxicology Research, Others) and By End-User (Pharmaceutical Companies, Research Organizations, Others) - Forecast to 2035

US Organ-on-Chip Market Overview

As per MRFR analysis, the US Organ-on-Chip Market Size was estimated at 16.5 (USD Million) in 2023. The US Organ-on-Chip Market Industry is expected to grow from 18.43 (USD Million) in 2024 to 111.09 (USD Million) by 2035. The US Organ-on-Chip Market CAGR (growth rate) is expected to be around 17.737% during the forecast period (2025 - 2035).

Key US Organ-on-Chip Market Trends Highlighted

The US Organ-on-Chip Market is witnessing significant trends shaped by advancements in biotechnology and regulatory support. Key market drivers include the growing demand for more efficient drug development processes and the reduction of animal testing in research, aligning with ethical considerations and policies from organizations like the FDA that encourage alternative methods.

Researchers are increasingly adopting organ-on-chip technology for its ability to mimic human physiology, leading to faster and more effective drug screening and toxicity testing. Opportunities in this market are emerging due to the increasing collaboration between academic institutions and biotechnology firms in the United States.

This partnership is fostering innovation and addressing specific healthcare needs, such as personalized medicine and tailored drug therapies. As universities and research facilities continue to develop sophisticated organ-on-chip models, it opens the door for new applications in regenerative medicine and disease modeling, leading to further investment and interest in this technology.

Recent trends highlight a growing acceptance of organ-on-chip systems by regulatory bodies in the US, which is crucial for their integration into the broader biomedical research landscape. There is also an increasing focus on developing multi-organ systems that can provide a more comprehensive understanding of human biology and drug responses.

Furthermore, advancements in microengineering and materials science are enhancing the capabilities of organ-on-chip devices, making them more accessible for various applications in pharmaceutical research and toxicology. As these trends continue to evolve, the US organ-on-chip market is poised for significant growth and innovation in the coming years.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Organ-on-Chip Market Drivers

Increase in Pharmaceutical Research and Development Activities

The surge in pharmaceutical Research and Development (R&D) activities in the United States is a significant driver for the US Organ-on-Chip Market Industry. The Pharmaceutical Research and Manufacturers of America (PhRMA) reported that the pharmaceutical industry invested over 83 billion USD annually in R&D as of 2021.

With the increasing complexity of drug development and the need for more predictive preclinical models, pharmaceutical companies are increasingly adopting Organ-on-Chip technology. This technology allows for more accurate human-relevant data, reducing the time and cost associated with clinical trials.

Noteworthy organizations like Johnson & Johnson and Pfizer are heavily investing in Organ-on-Chip systems to enhance their drug discovery processes, significantly contributing to the growth of this market. Additionally, the Food and Drug Administration (FDA) has begun to recognize the importance of such technologies in regulatory decision-making, which further propels market adoption.

As the US pharmaceutical market continues to showcase robust growth, driven by innovation and technology, the US Organ-on-Chip Market Industry is expected to expand substantially in line with these R&D investments and advancements in regulatory acceptance.

Rising Demand for Personalized Medicine

The increasing emphasis on personalized medicine in the United States is another critical driver influencing the US Organ-on-Chip Market Industry. According to the American Society of Clinical Oncology (ASCO), approximately 50% of all cancer treatments are now tailored to individual genetic markers.

This rise in personalized approaches necessitates the use of Organ-on-Chip systems to develop patient-specific models for drug testing and evaluation. The integration of microfluidic technology in these systems allows researchers to mimic the physiology of individual patients, enabling better customization of therapies.

Established organizations such as Amgen are actively investing in advanced Organ-on-Chip research to support personalized treatment paradigms. With the US healthcare system gradually shifting towards precision medicine, the growing demand for such adaptable and precise models will likely bolster the Organ-on-Chip market significantly.

Government Initiatives Supporting Advanced Biotechnologies

The United States government has been proactive in supporting advancements in biomedical technologies, which is a vital factor aiding the US Organ-on-Chip Market Industry's growth. The National Institutes of Health (NIH) has announced funding initiatives exceeding 1 billion USD toward biomedical innovations that streamline drug testing processes and improve clinical outcomes.

These investments include grant programs specifically aimed at fostering the development of Organ-on-Chip technologies, encouraging universities, and startups to innovate. Organizations like the National Cancer Institute are collaborating with private sector companies to integrate organ-on-chip studies into their existing research frameworks.

This governmental backing not only legitimizes the significance of Organ-on-Chip technology but also fosters a supportive ecosystem that propels industry growth, influencing the integration of such advancements in clinical and research settings.

US Organ-on-Chip Market Segment Insights

Organ-on-Chip Market Organ Type Insights

The US Organ-on-Chip Market is gaining significant traction, driven by innovations in biomedical engineering and the urgent need for more effective drug development and testing platforms. The Organ Type segment includes crucial models such as the Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, and Human-on-Chip, each playing a pivotal role in advancing research and development across various healthcare applications.

The Lung-on-Chip mimics human lung physiology, providing an invaluable tool for studying respiratory diseases and drug responses, reflecting the critical nature of respiratory health in the United States, where chronic lung diseases significantly impact public health. The Heart-on-Chip model serves as an essential platform to assess cardiac drug safety and efficacy, addressing the growing burden of cardiovascular diseases in the nation.

Liver-on-Chip is particularly significant in the realm of pharmacokinetics, allowing researchers to study drug metabolism and toxicity, which is vital given that liver-related ailments account for a substantial percentage of healthcare costs. The Intestine-on-Chip system offers insights into gastrointestinal disorders and can improve the understanding of gut microbiome interactions with drugs, showcasing the rising focus on personalized medicine and microbiome research.

Kidney-on-Chip technology plays an important role in renal drug toxicity studies and disease modeling, which correlates with the increasing prevalence of kidney disorders among the US population. Lastly, the Human-on-Chip represents the convergence of multiple organ systems, enabling more holistic assessments of therapeutic interventions, which is pivotal for regulatory compliance and patient safety in drug development processes.

This diverse range of organ models significantly enhances the US Organ-on-Chip Market segmentation by providing tailored solutions for drug testing, disease modeling, and personalized medicine, ultimately supporting the need for more effective and ethical alternatives to traditional animal testing methods. The demand for these sophisticated models also aligns with various governmental initiatives aimed at fostering innovative biotechnological advances and improving healthcare outcomes in the United States.

As the landscape shifts towards more organ-specific analytical approaches, the Organ Type segment will likely witness continued growth, positioning itself as a cornerstone in the evolution of precision medicine and biopharmaceutical development. With these advancements at the forefront, the overall market dynamics promise a robust evolution, ultimately enhancing the efficiency and effectiveness of the healthcare system in the US.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Organ-on-Chip Market Application Insights

The Application segment of the US Organ-on-Chip Market is gaining attention due to its transformative potential in various fields, particularly Drug Discovery and Toxicology Research. This segment is vital as it offers innovative ways to model human organ systems, enabling researchers to study drug interactions and toxicological responses effectively.

Drug Discovery holds a significant role in the market, as it enhances the efficiency of preclinical testing by reducing reliance on traditional animal models, thereby aligning with a growing demand for ethical and more predictive approaches in pharmaceuticals. Toxicology Research also plays an important role, allowing for safer and more precise evaluations of chemical exposures and their effects on human health.

As the industry shifts towards personalized medicine, these applications facilitate tailored therapies and quicker drug approvals, addressing both market growth and regulatory demands. The US is at the forefront of such innovations, supported by various initiatives aimed at advancing biomedical research and improving healthcare outcomes. Overall, the Application segment is expected to continue developing as critical advancements transpire within the US Organ-on-Chip Market.

Organ-on-Chip Market End-User Insights

The US Organ-on-Chip Market is significantly influenced by its End-User segment, comprising Pharmaceutical Companies, Research Organizations, and others. Pharmaceutical Companies play a crucial role in leveraging organ-on-chip technology for drug development and testing, which enhances the accuracy of preclinical studies and reduces the reliance on animal testing.

This segment's growth is driven by increasing investments in innovative drug delivery systems and a rising emphasis on personalized medicine. Research Organizations are also vital, as they utilize organ-on-chip platforms to explore disease mechanisms and therapeutic responses in a controlled environment, allowing for groundbreaking advancements in the field of biomedicine.

By offering a more human-relevant model for research, they contribute significantly to the overall success of the technology. The presence of regulatory support and funding from various governmental agencies promotes the adoption of organ-on-chip systems in these sectors, leading to a broader market expansion. Meanwhile, other users of this technology, including academia and health institutions, are also becoming essential contributors, exploring various applications and driving further innovation within the US Organ-on-Chip Market landscape.

Key factors such as increased demand for advanced in vitro models and the expansion of healthcare research are driving the overall market growth, making it a dynamic and promising industry segment.

US Organ-on-Chip Market Key Players and Competitive Insights

The US Organ-on-Chip Market has rapidly evolved, reflecting significant advancements in biotechnology and drug development processes. This market focuses on the integration of biological and mechanical systems to create microphysiological models that can mimic human organ functions. These models offer invaluable insights into drug efficacy and toxicity, thereby providing a powerful alternative to traditional testing methods.

With increasing investment from both public and private sectors, the competitive landscape is marked by a diverse array of companies vying for market share and technological superiority, indicating a dynamic and rapidly growing sector. The race for developing more sophisticated and functional organ-on-chip systems has become a key driver of innovation, ultimately enhancing the capabilities of research and development within the pharmaceutical industry and other related sectors.

In the context of the US Organ-on-Chip Market, InSphero has established a formidable presence, particularly known for its expertise in developing 3D cell culture technology that facilitates drug testing and toxicology studies. The company’s pioneering techniques enable researchers to replicate organ functionalities more accurately, thereby enhancing the predictive power of in vitro models.

One of the cardinal strengths of InSphero lies in its customized solutions which cater to both research and commercial applications, effectively bridging the gap between basic research and clinical application. Their collaborative efforts with academic institutions and other biotech firms further underscore their commitment to advancing organ-on-chip technology, positioning them as a leader in this niche market segment.

VitroLabs has carved a niche in the US Organ-on-Chip Market with its innovative approaches to regenerative medicine and organ modeling. Focusing on the development of organ-on-chip systems that mimic complex organ functions, VitroLabs provides key products and services that are particularly advantageous for pharmaceutical research and toxicology assessments.

The company's strengths include advanced bioengineering capabilities and strategic partnerships which bolster its market presence. Notably, VitroLabs has engaged in various collaborations and potential mergers that enhance their research capabilities, all while maintaining a strong commitment to regulatory standards, further establishing confidence in their technology. Their continuous investment in R&D further solidifies their position as a noteworthy competitor in the rapidly evolving organ-on-chip landscape in the United States.

Key Companies in the US Organ-on-Chip Market Include

• InSphero


• VitroLabs


• NCardia


• Emulate


• Ascendance Bio


• Hurel Corporation


• Organovo


• CureMetrix


• Mimic Technologies


• Pulmodynamics


• Biomimetic Solutions


• TissUse


• Synlogic


• Tara Biosystems

US Organ-on-Chip Market Industry Developments

The US Organ-on-Chip Market has seen significant developments recently, with companies like Emulate and Organovo making strides in their respective technologies to better mimic human organ functions for drug testing and disease modeling. In addition, InSphero has been advancing its 3D tissue models, enhancing the capabilities of Organ-on-Chip applications in pharmaceutical research.

Critical partnerships have formed, such as between Mimic Technologies and industry leaders to expand their product offerings in tissue engineering solutions. As of September 2023, a merger was publicly announced involving Hurel Corporation and Naefin Technologies, aimed at enhancing their organ-on-chip systems to improve drug screening accuracy, which was positively viewed by investors.

Market valuations in the Organ-on-Chip sector reflect a robust growth trajectory, driven by increasing adoption in Research and Development sectors, with many companies reporting accelerated revenue growth in recent quarters. Additionally, TissUse’s expansion into new markets has further solidified its position in the organ-on-chip space, supporting the overall industry momentum.

US Organ-on-Chip Market Segmentation Insights

Organ-on-Chip Market Organ Type Outlook

• Lung-on-Chip


• Heart-on-Chip


• Liver-on-Chip


• Intestine-on-Chip


• Kidney-on-Chip


• Human-on-Chip

Organ-on-Chip Market Application Outlook

• Drug Discovery


• Toxicology Research


• Others

Organ-on-Chip Market End-User Outlook

• Pharmaceutical Companies


• Research Organizations


• Others

Report Scope:

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	16.5(USD Million)
MARKET SIZE 2024	18.43(USD Million)
MARKET SIZE 2035	111.09(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	17.737% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	InSphero, VitroLabs, NCardia, Emulate, Ascendance Bio, Hurel Corporation, Organovo, CureMetrix, Mimic Technologies, Pulmodynamics, Biomimetic Solutions, TissUse, Synlogic, Tara Biosystems
SEGMENTS COVERED	Organ Type, Application, End-User
KEY MARKET OPPORTUNITIES	Increased pharmaceutical R&D investment, Rising demand for personalized medicine, Advancements in biotechnology innovations, Strong government support for research, Growth in disease modeling applications
KEY MARKET DYNAMICS	Innovative drug development methods, Rising demand for personalized medicine, Increasing investment in biotechnology, Regulatory support for organ-on-chip, Growing prevalence of chronic diseases
COUNTRIES COVERED	US